J. Sampson

Publications533
h-index86
Citations26,163
Highly Influential Citations828
Claim Author Page
Author pages are created from data sourced from our academic publisher partnerships and public sources.

Recommended Authors

  • D. Bigner
  • 881 Publications • 79,719 Citations
  • H. Friedman
  • 835 Publications • 52,912 Citations
  • D. Reardon
  • 710 Publications • 38,387 Citations
  • S. Rosenberg
  • 1,497 Publications • 208,544 Citations
  • Publications
  • Influence
Bevacizumab plus irinotecan in recurrent glioblastoma multiforme.
TLDR
Bvacizumab and irinotecan is an effective treatment for recurrent glioblastoma multiforme and has moderate toxicity.
View on PubMed
Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma.
TLDR
EGFRvIII-targeted vaccination in patients with GBM warrants investigation in a phase III, randomized trial.
View on PubMed
Phase II trial of gefitinib in recurrent glioblastoma.
TLDR
Gefitinib is well tolerated and has activity in patients with recurrent glioblastoma and further study of this agent at higher doses is warranted.
View on PubMed
Increased regulatory T-cell fraction amidst a diminished CD4 compartment explains cellular immune defects in patients with malignant glioma.
TLDR
T(reg) removal eradicates T-cell proliferative defects and reverses T(H)2 cytokine shifts, allowing T cells from patients with malignant glioma to function in vitro at levels equivalent to those of normal, healthy controls and advance a role for T(regs) in facilitating tumor immune evasion in the central nervous system.
View on PubMed
Demographics, prognosis, and therapy in 702 patients with brain metastases from malignant melanoma.
TLDR
A retrospective review of patients with melanoma treated at a single institution was undertaken to identify demographic factors associated with the development of clinically significant brain metastases and to determine the factors influencing the prognosis of this population to permit more informed recommendations regarding surgical therapy.
View on PubMed
Immunotherapy response assessment in neuro-oncology: a report of the RANO working group.
View on PubMed
Sensitive detection of human cytomegalovirus in tumors and peripheral blood of patients diagnosed with glioblastoma.
TLDR
It is demonstrated that subclinical HCMV viremia (presence of viral DNA in blood without clinical symptoms of infection) is a previously unrecognized disease spectrum in patients with GBM.
View on PubMed
Direct intracerebral delivery of cintredekin besudotox (IL13-PE38QQR) in recurrent malignant glioma: a report by the Cintredekin Besudotox Intraparenchymal Study Group.
TLDR
CED is a complex delivery method requiring catheter placement via a second procedure to achieve accurate catheter positioning, better drug distribution, and better outcome, and appears to have a favorable risk-benefit profile.
View on PubMed
Surgical Management of Petroclival Meningiomas: Defining Resection Goals Based on Risk of Neurological Morbidity and Tumor Recurrence Rates in 137 Patients
TLDR
Intraoperatively defined tumor characteristics played a critical role in identifying the subset of patients with an increased risk of postoperative deficits and selectively pursuing an NTR rather than a GTR, neurological morbidity was reduced significantly without significantly increasing the rate of tumor recurrence.
View on Wolters Kluwer
Recurrent Glioblastoma Treated with Recombinant Poliovirus
TLDR
Intratumoral infusion of PVSRIPO in patients with recurrent WHO grade IV malignant glioma confirmed the absence of neurovirulent potential and the survival rate among patients who received PVSRipO immunotherapy was higher at 24 and 36 months than the rate among historical controls.
View on Wolters Kluwer
...
...